GSDMB is frequently co-expressed with HER2/Erbb2 oncogene in breast and gastric carcinomas [39, 40], where GSDMB over-expression promotes tumorigenesis [41], invasion, metastasis, and resistance to therapy [39, 42]. This evidence concerns the gene ERBB2 and gastric carcinoma.